Sun Pharma to Acquire Organon for $11.75 Billion, Boosting Global Presence

Sun Pharmaceutical Industries Limited, India's largest pharmaceutical company, has announced a definitive agreement to acquire the US-listed global healthcare company, Organon & Co., in an all-cash transaction valued at an enterprise of $11.75 billion. This landmark deal, publicly announced on April 26-27, 2026, represents one of the most significant outbound acquisitions by an Indian company and is poised to reshape Sun Pharma's global market position. Under the terms of the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash. The transaction has received approval from the boards of both companies and is anticipated to conclude in early 2027, subject to customary closing conditions, including regulatory clearances and Organon stockholder approval. Shares of Sun Pharmaceutical Industries saw a significant jump, rising over 7% on the BSE and NSE following the acquisition announcement, reflecting positive market sentiment towards the strategic move. Organon & Co. was established in 2021 as a spinoff from Merck & Co. (known as MSD outside the U.S. and Canada), becoming an independent global healthcare company. It specializes in key therapeutic areas, particularly women's health, which is a significant part of its portfolio. Organon's product lineup comprises over 70 products spanning women's health, biosimilars, and general medicines, commercialized across more than 140 countries, with major markets including the U.S., Europe, China, Canada, and Brazil. The company also operates six manufacturing facilities situated across the European Union and emerging markets. For the year ended December 31, 2025, Organon reported revenues of $6.2 billion and an Adjusted EBITDA of $1.9 billion. The company carried a debt of $8.6 billion and a cash balance of $574 million at the end of 2025. Sun Pharma plans to fund the substantial acquisition through a combination of its available cash resources and committed financing from banks. The acquisition is strategically aligned with Sun Pharma's long-term vision to bolster its innovative medicines business and expand its global presence. By integrating Organon's complementary portfolio and capabilities, Sun Pharma expects to become a stronger player in the Established Brands/Branded Generics segment. Crucially, the deal facilitates Sun Pharma's entry into the biosimilars market as a top-10 global player and positions the combined entity among the top three companies in global women's health, creating a robust commercial platform for sustained growth. Upon successful completion, the combined company is projected to achieve pro forma revenues of approximately $12.4 billion, placing it among the top 25 global pharmaceutical companies. Sun Pharma anticipates realizing synergies exceeding $350 million within two to four years post-acquisition. The transaction structure involves a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. This strategic maneuver is expected to enhance Sun Pharma's cash generation, with EBITDA and cash flow projected to nearly double, supporting deleveraging from a post-transaction net debt-to-EBITDA ratio of 2.3x. Executive Chairman of Sun Pharma, Dilip Shanghvi, emphasized that Organon's portfolio, capabilities, and global reach are highly complementary to Sun Pharma's existing strengths, creating a more diversified and powerful platform. The legal and financial advisory roles for this monumental deal are handled by prominent firms. J.P. Morgan Securities LLC and Jefferies LLC are serving as financial advisors to Sun Pharma, with White & Case LLP providing legal counsel globally and AZB & Partners advising on India-related legal matters. Organon is being advised by Morgan Stanley and Goldman Sachs as financial advisors, and Covington & Burling LLP as legal counsel. This major acquisition highlights Sun Pharma's aggressive strategy for global expansion and its commitment to strengthening its presence in key therapeutic areas, making it a significant development for the pharmaceutical industry in India and worldwide.

Frequently Asked Questions

Read Full Story on Quick Digest